The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by ...

NEOK Bio, Inc., a biotechnology company focused on the development of novel antibody drug conjugates (ADCs) for improving ...

Merck said on Tuesday that it has entered into an agreement to receive funds managed by Blackstone Life Sciences for $700 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences ...

Neok Bio has exited stealth with $75 million to take a pair of bispecific antibody-drug conjugates sourced from ABL Bio into ...

Based on strong preclinical data on HMPL-A251 in HER2-positive tumor cell lines, the firm wants to take the therapy into clinical trials by year end.

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug ...

These pivotal studies investigated AstraZeneca and Daiichi Sankyo’s Enhertu, a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate with a topoisomerase II-targeting ...

Xcellon Biologics will incorporate IntoCell’s OHPAS drug-linker system into its range of ADC development suites.

Central Virginia On Oct. 9, AstraZeneca announced it will invest $4.5 billion to establish two pharmaceutical manufacturing facilities in Albemarle County, with plans to create 600 jobs. According to ...

HUTCHMED unveils its innovative ATTC platform, potentially providing precision oncology with synergistic dual-mechanism of action —— Lead ...